STAAR Surgical (STAA) Tops Q1 EPS by 5c, Beats on Revenue
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Dow tick higher as investors weigh Mideast negotiations
- Oil falls after US-Iran talks signal easing supply risks
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
- Sanuwave cuts Q2 2026 revenue guidance amid Ultramist sales pressure
STAAR Surgical Reports First Quarter 2026 Results; Issues Shareholder Letter
May 13, 2026 4:01 PM EDTNet Sales of $93.5 million, highest first quarter Net Sales in Companys history, up 119.6% Y/Y
Net Income of $5.2 million, with GAAP EPS of $0.10
Adjusted EBITDA1 of $24.4 million, or $0.48 per diluted share
Earnings Call and Webcast Today at 5:30 PM Eastern
LAKE FOREST, Calif.--(BUSINESS WIRE)-- STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL) for vision correction, today reported results for the first quarter... More
